Please assess the completion status of the following clinical trial:

Trial Title: DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with primary open angle glaucoma or ocular hypertension~* Provided signed, written informed consent~* 20 years of age and older~* If a subject is a female of childbearing potential, she must utilize reliable contraceptive throughout the study, and must have a negative urine pregnancy test prior to enrollment into this study.~Exclusion Criteria:~* Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception.~* Presence of any abnormality or significant illness that could be expected to interfere with the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- 1 (Type: EXPERIMENTAL): DE-111 ophthalmic solution
- 2 (Type: ACTIVE_COMPARATOR): Tafluprost ophthalmic solution 0.0015%
- 3 (Type: ACTIVE_COMPARATOR): Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%

Based on this trial design, predict the completion outcome and termination type (if applicable).